Predict your next investment

Private Equity
n-ci.com

See what CB Insights has to offer

Investments

63

Portfolio Exits

4

Funds

9

Partners & Customers

2

About NCI

NCI, a major capital investment offers entrepreneurs a potential of more than € 110 million capital project dedicated to the creation, development and transmission companies. These funds, underwritten by institutional investors both public and private, allow NCI to be a true independent financial tool for the economic development of its territory Normandy.

NCI Headquarter Location

57 Avenue de Bretagne

Rouen, 76100,

France

02 32 18 63 02

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NCI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find NCI in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Microbiome

105 items

Research containing NCI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned NCI in 1 CB Insights research brief, most recently on Jul 26, 2019.

NCI Investments

63 Investments

NCI has made 63 investments. Their latest investment was in UpCiti as part of their Series A on May 5, 2021.

CBI Logo

NCI Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/3/2021

Series A

UpCiti

$4.58M

Yes

2

2/3/2021

Series A

Scalinx

$12.63M

Yes

2

11/10/2020

Seed VC

iNex Circular

$1.18M

Yes

1

7/16/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/3/2021

2/3/2021

11/10/2020

7/16/2020

3/10/2020

Round

Series A

Series A

Seed VC

Series B

Series A

Company

UpCiti

Scalinx

iNex Circular

Subscribe to see more

Subscribe to see more

Amount

$4.58M

$12.63M

$1.18M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

NCI Portfolio Exits

4 Portfolio Exits

NCI has 4 portfolio exits. Their latest portfolio exit was Youboox on October 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/7/2021

Acquired

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/7/2021

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

NCI Acquisitions

19 Acquisitions

NCI acquired 19 companies. Their latest acquisition was Herbolistique on May 27, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/27/2021

Acq - Fin

2

1/8/2021

Acq - Fin

1

12/6/2018

Private Equity

$14.79M

Shareholder Liquidity

1

1/16/2018

Subscribe to see more

$99M

Subscribe to see more

10

11/20/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/27/2021

1/8/2021

12/6/2018

1/16/2018

11/20/2014

Investment Stage

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$14.79M

$99M

$99M

Note

Acq - Fin

Acq - Fin

Shareholder Liquidity

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

NCI Fund History

9 Fund Histories

NCI has 9 funds, including Reprendre & Developper 4.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/30/2017

Reprendre & Developper 4

Diversified Private Equity

$92.05M

1

12/31/2013

Reprendre & Developper 2

Subscribe to see more

$99M

10

12/31/2008

Major Capital

Subscribe to see more

$99M

10

12/31/2008

Normandie Creation 1

Subscribe to see more

$99M

10

6/30/2008

Croissance et Proximite 2

Subscribe to see more

$99M

10

Closing Date

1/30/2017

12/31/2013

12/31/2008

12/31/2008

6/30/2008

Fund

Reprendre & Developper 4

Reprendre & Developper 2

Major Capital

Normandie Creation 1

Croissance et Proximite 2

Fund Type

Diversified Private Equity

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$92.05M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

NCI Partners & Customers

2 Partners and customers

NCI has 2 strategic partners and customers. NCI recently partnered with Multiple Myeloma Research Foundation on February 2, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

2/14/2017

Partner

Multiple Myeloma Research Foundation

United States

NCI collaborates with Multiple Myeloma Research Foundation

The National Cancer Institute announced a collaboration with the Multiple Myeloma Research Foundation to incorporate MMRF 's wealth of genomic and clinical data about the disease into the National Cancer Institute , a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology .

1

4/20/2015

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/14/2017

4/20/2015

Type

Partner

Vendor

Business Partner

Multiple Myeloma Research Foundation

Country

United States

Subscribe to see more

News Snippet

NCI collaborates with Multiple Myeloma Research Foundation

The National Cancer Institute announced a collaboration with the Multiple Myeloma Research Foundation to incorporate MMRF 's wealth of genomic and clinical data about the disease into the National Cancer Institute , a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology .

Subscribe to see more

Subscribe to see more

Sources

1

10

NCI Team

5 Team Members

NCI has 5 team members, including current Chief Executive Officer, Jean-Marc Buchet.

Name

Work History

Title

Status

Jean-Marc Buchet

Chief Executive Officer

Current

Greg Firestone

Chief Executive Officer

Current

Gerard Lissot

President

Current

Philip Isham COE OCS

Chief Operating Officer, Senior Vice President

Former

Tim Tignor

Senior Vice President

Former

Name

Jean-Marc Buchet

Greg Firestone

Gerard Lissot

Philip Isham COE OCS

Tim Tignor

Work History

Title

Chief Executive Officer

Chief Executive Officer

President

Chief Operating Officer, Senior Vice President

Senior Vice President

Status

Current

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.